Astellas and Cullgen enter inks agreement to advance innovative targeted protein degraders
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg had annual sales of USD 13 mn in the United States
Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
Pfizer is likely to show GSK significant competition
UTD2 is the world's first oral epothilone microtubule inhibitor
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
The new recycling facility, Recover Louth, is the second addition to Coveris’ closed loop recycling business segment
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Jain will have oversight of Brinton's domestic operations, including business development, sales, and marketing
Subscribe To Our Newsletter & Stay Updated